Articles tagged "Hepatitis C"

2022 American Transplant Congress
BK Polyomavirus and Cytomegalovirus Infections in Kidney Transplantation from Hepatitis C Positive Donors to Uninfected Recipients
I. Yakubu, V. Amrutiya, I. Moinuddin, M. Levy, G. Gupta, A. Azhar
Virginia Commonwealth University, Richmond, VA
*Purpose: Transplantation of hepatitis C viremic (HCV) donor kidneys into uninfected recipients (D+/R-) is becoming more common in the United States. However, the long-term risks…
2022 American Transplant Congress
Current State of Use of Hepatitis C Viremic Donor Organs in Negative Recipients in the United States: A National Survey
K. Ryland¹, K. Hattori², J. Steinbrink³, N. Theodoropoulos⁴, M. Ison⁵
¹Mayo Clinic, Jacksonville, FL, ²Duke university hospital, Durham, NC, ³Duke University, Durham, NC, ⁴University of Massachusetts Medical School, Worcester, MA, ⁵Northwestern University Comprehensive Transplant Center, Chicago, IL
*Purpose: Since the advent of direct-acting antiviral (DAA) therapy, use of hepatitis C (HCV) viremic donor organs in HCV negative recipients has become more common.…
2022 American Transplant Congress
Eliminating Hepatitis C Positive Status from Kidney Donor Profile Index (KDPI) Calculations Results in Improved Transplant Rates and Outcomes in an Elderly Veteran Population
R. Lopez-Soler¹, A. Thorndyke¹, C. Trotter¹, A. Abadier², M. Samra¹
¹Surgery, Transplantation, Edward Hines Jr. Veterans Administration Hospital, Hines, IL, ²Surgery, Loyola University Medical School, Maywood, IL
*Purpose: Overall mortality on the kidney transplant waiting list is higher for older patients. The average age of waitlisted veteran patients is 64, with patients…
2022 American Transplant Congress
Expanded Experience with Ultra-Short Duration Pangenotypic Direct Acting Anti-Viral (DAA) Prophylaxis to Prevent Virus Transmission from Hepatitis C Viremic (HCV) Donors to Hepatitis C Negative Kidney Transplant Recipients (KT)
I. Yakubu, D. Kumar, A. Sharma, M. Levy, L. Kamal, G. Gupta
Virginia Commonwealth University, Richmond, VA
*Purpose: Previous studies have shown that HCV D+/R- kidney transplantation is feasible using 8-12 weeks of DAAs. Utilization of abbreviated regimens may obviate the need…
2022 American Transplant Congress
Outcomes Following Renal Transplant with Hepatitis C Viremic Donors in an Elderly Veteran Population with Preemptive Mayvret Therapy
R. Lopez-Soler¹, A. Thorndyke¹, C. Trotter¹, A. Abadier², M. Samra¹
¹Surgery, Transplantation, Edward Hines Jr. Veterans Administration Hospital, Hines, IL, ²Surgery, Loyola University School of Medicine, Maywood, IL
*Purpose: Overall mortality on the kidney transplant waiting list is higher for older diabetic patients. The average age of waitlisted veteran patients is 64, with…
2022 American Transplant Congress
Decision-Making Among HCV-Negative Transplant Candidates Offered Organs from Donors with HCV Infection
E. Schnellinger¹, E. Saine¹, M. Liu¹, J. Diamond¹, M. Crespo¹, S. Prenner¹, V. Potluri¹, C. Bermudez¹, H. Mentch¹, M. Moore², B. Besharatian¹, D. Goldberg³, F. Barg¹, P. Reese¹
¹University of Pennsylvania, Philadelphia, PA, ²University of London, London, United Kingdom, ³University of Miami, Miami, FL
*Purpose: Historically, many organs from deceased donors with hepatitis C virus (HCV) infection were discarded due to stigma and challenges in treating HCV after transplant.…
2022 American Transplant Congress
The SHELTER Trial of Transplanting Donor Hepatitis C Virus RNA+ Lungs Into Uninfected Recipients
V. Potluri¹, P. Reese¹, S. Prenner¹, H. Mentch¹, D. Goldberg², T. Claridge¹, J. Smith¹, C. Gentile¹, V. Van Deerlin¹, R. Reddy¹, T. Fallah¹, C. Bermudez¹, M. Crespo¹, J. Diamond¹
¹University of Pennsylvania, Philadelphia, PA, ²University of Miami, Miami, FL
*Purpose: The advent of direct acting antiviral therapy has motivated centers to transplant lungs from donors with hepatitis C virus infection (HCV-RNA+) into uninfected recipients.…
2022 American Transplant Congress
Evaluation of Hepatitis C Positive Donor to Hepatitis C Negative Recipient Kidney Transplant in a Highly Sensitized Patient Population
A. T. Iaria, M. Martin, A. Hietpas, I. Tang, S. Koppe, I. Tzvetanov, E. Benedetti, C. Muran
University of Illinois at Chicago, Chicago, IL
*Purpose: This study assessed outcomes of hepatitis C virus (HCV) donor positive to recipient negative (D+/R-) kidney transplants (KT) in high immunologic risk patients. Literature…
2022 American Transplant Congress
CMV Specific T Cell Immune Response in Hepatitis C Negative Kidney Transplant Recipients Receiving Transplant from Hepatitis C Viremic Donors and Hepatitis C Negative Donors
M. Z. Molnar¹, M. Tsujita², M. Talwar², V. Balaraman², A. Bhalla², J. D. Eason², S. S. Nouer², K. Sumida², A. Remport³, I. E. Hall¹, R. Griffin², G. George Rofaiel⁴, A. Azhar⁵
¹Department of Internal Medicine, Division of Nephrology & Hypertension, University of Utah, Salt Lake City, UT, ²University of Tennessee Health Science Center, Memphis, TN, ³Semmelweis University, Budapest, Hungary, ⁴Department of Surgery, Division of Transplantation and Advanced Hepatobiliary Surgery, University of Utah, Salt Lake City, UT, ⁵Division of Nephrology, Department of Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA
*Purpose: Kidney transplants (KT) from hepatitis C (HCV) viremic donors to HCV negative recipients has shown promising short-term and long-term outcomes. However, high incidence of…
2022 American Transplant Congress
National Consortium Registry Insights on Management and Outcome of Hepatitis C Viremic Heart Transplants
R. Gottlieb¹, M. Salem¹, A. Ravichandran², J. Kennedy³, J. Strope⁴, S. Lin⁵, J. Chow⁶, P. Eckman⁷, S. Desai⁸, O. Larkins¹, J. Vanzyl¹, S. Hall¹
¹Baylor Scott & White Healthcare, Dallas, TX, ²Ascension Medical Group, Indianapolis, IN, ³Inova Heart and Vascular Institute, Falls Church, VA, ⁴Medical University of South Carolina, Charleston, SC, ⁵University of Washington Medical Center, Seattle, WA, ⁶Tufts Medical Center, Boston, MA, ⁷Minneapolis Heart Institute, Minneapolis, MN, ⁸Ochsner Medical Center, New Orleans, LA
*Purpose: Multicenter US registry of clinical management of HCV NAT+ hearts.*Methods: An ongoing 8-center retrospective IRB-approved registry collected baseline characteristics, labs, management, and outcomes after…

1
2
3
…
28
Next Page »